European Innovation Council

Brevel has developed an innovative cultivation technology focused on the sustainable and cost-effective production of microalgae. Utilizing high-tech, fully automated indoor systems that feature internal illumination, Brevel's approach achieves significant cost reductions and substantially higher yields compared to traditional methods. This advanced technology positions the company to tap into various markets in need of microalgae-derived products, including sustainable food, materials, chemicals, pharmaceuticals, and energy. By unlocking the full potential of microalgae, Brevel aims to create an alternative protein source suitable for mass production, addressing the increasing demand for environmentally friendly solutions across multiple industries.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for targeted cancer therapies. Founded in 2015, the company has established a proprietary drug delivery platform, Sagitta®, which enables the design of targeted drug candidates for various indications. RS Research's pipeline includes several proprietary programs in different stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. In addition to drug development, RS Research offers a range of services, including preclinical absorption, distribution, metabolism, and excretion studies, bioanalytical and analytical testing, and patent consulting. The company operates a GMP-certified production facility for clinical batch drug candidates and has successfully engaged in co-development projects with international partners, showcasing its commitment to advancing cancer treatment through modern therapeutic approaches.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Kvantify, founded in 2022 and headquartered in Copenhagen, Denmark, specializes in quantum computing management software aimed at addressing complex computational challenges across various sectors, including life sciences, financial services, and logistics. The company's platform focuses on enhancing drug discovery processes by employing proprietary physics-based methods to improve the quality of compounds tested in laboratories. By providing advanced computational drug technology, Kvantify enables life sciences companies to accelerate small molecule research and obtain actionable results that significantly impact their operations.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

Gate2Brain is an early-stage biotech company dedicated to enhancing drug delivery across biological barriers, particularly the blood-brain barrier, through a patented peptide-based technology. This innovative platform aims to transport therapeutics directly to the brain, thereby improving the efficacy of treatments for neurological diseases and reducing associated side effects. Additionally, Gate2Brain focuses on developing therapeutics that can address rare pediatric cancers, positioning itself as a key player in advancing medical solutions for challenging conditions.

Vésale Pharma is a company dedicated to producing pharmaceutical products that aim to enhance health and well-being for individuals throughout their lives. Collaborating with internationally recognized research organizations, Vésale Pharma focuses on developing innovative healthcare solutions tailored to diverse needs. Their product range addresses various health concerns, including dermatology, gastroenterology, women's health, immunity, and pregnancy. Notably, the company's offerings are designed to have no side effects and are suitable for all body types, ensuring that patients can maintain their fitness and overall health.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

Qu & Co is a prominent developer of quantum-computational algorithms and software, focusing on the optimization of specialty chemicals, pharmaceuticals, and functional materials. The company’s software enhances in-house discovery and optimization processes by advancing novel quantum-computational chemistry methods and seamlessly integrating with existing chemistry and material-science workflows. This enables industries such as pharmaceuticals to conduct complex chemistry and multiphysics simulations on future quantum processors. In January 2022, Qu & Co merged with PASQAL, a leader in neutral atom-based quantum hardware, solidifying its position as a key player in the European quantum computing sector.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Abzu is a scientific artificial intelligence company founded in January 2018, with offices in Copenhagen, Denmark, and Barcelona, Spain. The company develops the QLattice, an innovative AI platform that aims to challenge conventional black box AI by providing transparent and explainable models. Abzu's technology is designed to assist pharmaceutical and biotech companies in accelerating drug development processes. By unlocking new disease mechanisms, discovering novel biomarkers, and validating multiple targets simultaneously, Abzu enables these companies to reduce research and development costs and enhance their discovery capabilities. Through its pioneering approach, Abzu inspires data scientists to adopt a more scientific methodology in their work.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

Nuclidium focuses on enhancing cancer detection and staging to improve treatment options and long-term survival for patients. The company develops innovative radiopharmaceutical tracers aimed at targeting cancer diagnostics. Its platform allows for the identification of specific target molecules on tumors, enabling the application of therapeutic tracers with similar chemical properties and biological targets. This approach aims to facilitate affordable and effective personalized treatment for cancer patients, addressing significant unmet needs in the field.

Swiss Airtainer specializes in the design and production of temperature-controlled containers for air transportation of pharmaceuticals. Their innovative unit load device, designed to streamline the cold chain, ensures energy efficiency, precise temperature regulation, secure storage, and real-time connectivity, providing clients with a cost-effective and reliable solution for their temperature-sensitive cargo.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

BrainEver focuses on developing innovative therapeutics for neurodegenerative disorders, rooted in the research of Alain Prochiantz and colleagues on brain development and physiology. The company explores the potential of homeoproteins, which are known to regulate neuronal functions throughout life, to enhance the physiological resistance and activity of surviving neurons in patients. This approach aims to improve clinical symptoms in conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company is advancing its lead candidate, Engrailed 1 (BREN01), while also working on a pipeline of additional drug candidates targeting other neurodegenerative diseases, including Huntington's disease and optic neuropathies. By developing these novel therapeutics, BrainEver aims to provide effective treatment options for healthcare practitioners and patients affected by these challenging conditions.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

EVerZom is a nanomedicine biotech company based in Paris, France, specializing in the large-scale manufacturing of extracellular vesicles. Founded in 2019, the company has developed a unique, GMP-compliant bioproduction platform aimed at pharmaceutical companies. This platform enables the production of various types of extracellular vesicles, including exosomes, microvesicles, and apoptotic bodies, which are essential for intercellular communication. EVerZom's products possess protective and reparative properties, making them valuable therapeutic tools in regenerative medicine and drug delivery. The company's technology is designed to assist healthcare professionals in addressing organ failure and restoring function and homeostasis.

Allero Therapeutics B.V. is a biopharmaceutical company based in Rotterdam, the Netherlands, founded in 2016. The company specializes in developing programmed immunotherapies aimed at treating immune-mediated disorders. Utilizing its Specific Oromucosal Immunotherapy (SOMIT) platform, Allero Therapeutics focuses on restoring immune tolerance through the targeted delivery of antigen-specific therapies. This innovative approach is based on research conducted by the founders and their collaborators, enabling the induction of long-lasting antigen-specific tolerance. The technology is designed to address a variety of clinical indications with significant unmet medical needs, particularly in the fields of allergic and autoimmune diseases.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.

Op2Lysis is a company focused on developing a neurotic drug aimed at treating hemorrhagic strokes. Its primary product is a thrombolytic agent designed to dissolve the intracerebral hematoma that develops after such strokes. This innovative treatment can be administered locally through a catheter, utilizing micro-invasive surgical techniques. By effectively liquefying the hematoma, Op2Lysis's therapy aims to help patients avoid significant disabilities and the need for extensive surgical procedures.

Fibriant is a biotechnology startup dedicated to the development and production of recombinant fibrinogen, a critical protein in blood that facilitates clotting and supports tissue repair and immune responses. The company operates a platform that produces flexible and biodegradable fibrinogen variants, which are designed to enhance processes such as wound healing and tissue remodeling. Fibriant's products aim to assist healthcare organizations in preventing complications, such as early and late-stage vein graft failure following bypass surgery, thereby improving patient outcomes in various medical applications.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

LiMM Therapeutics is a biopharmaceutical company focused on developing therapeutic agents aimed at addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal and innate lymphoid cells to create innovative products that aim to preserve health and improve patient outcomes. By bridging discoveries in neural sensing and immunology, LiMM Therapeutics seeks to unlock new therapeutic solutions that enhance immune regulation and combat infections. Through its research and development efforts, the company aspires to provide healthcare professionals with a pipeline of novel treatments to better manage various health conditions.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.

Fibriant is a biotechnology startup dedicated to the development and production of recombinant fibrinogen, a critical protein in blood that facilitates clotting and supports tissue repair and immune responses. The company operates a platform that produces flexible and biodegradable fibrinogen variants, which are designed to enhance processes such as wound healing and tissue remodeling. Fibriant's products aim to assist healthcare organizations in preventing complications, such as early and late-stage vein graft failure following bypass surgery, thereby improving patient outcomes in various medical applications.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Op2Lysis is a company focused on developing a neurotic drug aimed at treating hemorrhagic strokes. Its primary product is a thrombolytic agent designed to dissolve the intracerebral hematoma that develops after such strokes. This innovative treatment can be administered locally through a catheter, utilizing micro-invasive surgical techniques. By effectively liquefying the hematoma, Op2Lysis's therapy aims to help patients avoid significant disabilities and the need for extensive surgical procedures.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

PROSION is a biotechnology company focused on drug development, particularly in the area of cancer treatment and research. The company utilizes a proprietary platform that targets proline-rich motif binding domains, which are often associated with difficult-to-treat diseases. By employing innovative chemical building blocks, PROSION aims to unlock previously undruggable pharmaceutical targets linked to various pathologies, including cancer, diabetes, Alzheimer's, and cardiovascular diseases. This approach seeks to address significant unmet medical needs, ultimately enhancing treatment options and improving the survival and quality of life for patients.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective, safe, and disease-modifying treatment options. Hoba Therapeutics aims to offer relief and prevention for chronic pain and hearing loss, addressing significant medical needs for patients suffering from these conditions.

Roka Furadada is focused on reducing the incidence of skin cancer through the research, development, and production of innovative active ingredients and medical devices. The company specializes in creating an ultraviolet radiation filter designed to enhance sun protection. Its flagship product is an efficient sun cream that is photosensitive and environmentally friendly, with improved non-absorption properties. This formulation not only provides effective sun protection but also addresses health issues associated with sun exposure, allowing consumers to better safeguard their skin while minimizing toxicological and environmental impacts.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.

Separative is a startup focused on advancing the purification of molecules in organic chemistry and peptides. The company has developed innovative technology that enhances the efficiency and speed of purification processes for its clients. By utilizing specialized devices and columns, Separative enables companies in the healthcare and pharmaceutical sectors to separate a comprehensive range of chemical effects, moving beyond traditional methods that rely primarily on heat. This technology aims to streamline molecular separation, thereby improving overall operational effectiveness in various applications.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.

Separative is a startup focused on advancing the purification of molecules in organic chemistry and peptides. The company has developed innovative technology that enhances the efficiency and speed of purification processes for its clients. By utilizing specialized devices and columns, Separative enables companies in the healthcare and pharmaceutical sectors to separate a comprehensive range of chemical effects, moving beyond traditional methods that rely primarily on heat. This technology aims to streamline molecular separation, thereby improving overall operational effectiveness in various applications.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

LiMM Therapeutics is a biopharmaceutical company focused on developing therapeutic agents aimed at addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal and innate lymphoid cells to create innovative products that aim to preserve health and improve patient outcomes. By bridging discoveries in neural sensing and immunology, LiMM Therapeutics seeks to unlock new therapeutic solutions that enhance immune regulation and combat infections. Through its research and development efforts, the company aspires to provide healthcare professionals with a pipeline of novel treatments to better manage various health conditions.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in the development of biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients. The company's work is grounded in extensive scientific research conducted at Uppsala University and the Swedish University of Agriculture.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in the development of biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients. The company's work is grounded in extensive scientific research conducted at Uppsala University and the Swedish University of Agriculture.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.